GSK_ Annual_Report_2021-22

75 Business Responsibility and Sustainability Report Responsible business is how we do business Being commercially successful and operating responsibly is how we will generate sustainable returns for our shareholders and deliver on our purpose. We aim to bring differentiated, high quality and essential pharmaceuticals and vaccines to as many people as possible. Our three priorities – Innovation, Performance and Trust – help us realize our ambition for patients and drive robust growth for our shareholders and people to positively impact the health of millions of people. About this report The contents of this report are aligned with the 9 principles contained in the National Guidelines on Responsible Business Conduct (NGRBC) charted out by the Ministry of Corporate Affairs on Environmental, Social and Governance parameters for Financial Year (‘FY’) 2021-22. The report complies with the requirements for disclosing sustainability-related information aligned to the 9 principles of the NGRBC. Our disclosures around the non-financial performance indicators also seeks to enhance connectivity within your company’s general purpose financial reporting and the management of sustainability related impacts within our own operations. This report is our attempt at complying with the Business Responsibility and Sustainability Reporting as mandated under Regulation 34 of the Listing Regulations before it becomes mandatory from the next reporting cycle i.e., FY 2022-23. Careful consideration has been applied in reporting data which is true to the best of our knowledge and understanding of the reporting requirements. We are currently in the process of further strengthening our ESG data management systems to improve the quality of non-financial performance data disclosures for future reporting. The non-financial performance data reported herein has not been subjected to an independent third-party audit for the current FY. The disclosures under the extant Business Responsibility Report mandate are covered as Annexure B of the Director’s Report for FY 2021-22. Section A: General Disclosures Details of the listed entity 1. Corporate Identity Number (CIN) of your company L24239MH1924PLC001151 2. Name of your company GlaxoSmithKline Pharmaceuticals Limited (‘GSK’ or ‘your company’ or ‘we’) 3. Year of incorporation 1924 4. Registered office address GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr Annie Besant Road, Worli, Mumbai- 400030 5. Corporate address Same as above 6. E-mail in.investorquery@gsk.com 7. Telephone +91 22 24959595 8. Website https://india-pharma.gsk.com/en-in/ 9. Financial year for which reporting is being done FY 2021-22 10. Name of the stock exchange(s) where shares are listed BSE Ltd. (Bombay Stock Exchange) and the National Stock Exchange of India Ltd. (NSE). 11. Paid-up capital INR 16,940.60 lakh 12. Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report Name : Mr. Ajay Nadkarni Designation : Company Secretary Telephone no .: +91 22 2495 9595 Email ID: ajay.a.nadkarni@gsk.com 13. Reporting boundary Standalone basis